drugset / Trial / NCT04820751
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
Phase 3
Unknown
200 enrolled
Ciusss de L'Est de l'Île de Montréal
Covid-19 Early Treatment Fund · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
Timeline
- Start
- 2021-04-10
- Primary completion
- 2021-11-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyproheptadine | Small molecule | 4 mg | Oral |
| Subject | Cyproheptadine | Small molecule | 8 mg | Oral |